BCC 2023 | Duration of endocrine therapy in early breast cancer

Jens Huober, MD, Ulm University Hospital, Ulm, Germany, discusses the optimal duration of endocrine treatment in hormone receptor-positive patients with early breast cancer, highlighting current knowledge on the role of endocrine treatment, the risk of relapse during the course of the disease, as well as current trials which are evaluating extending endocrine therapy beyond five years. This interview took place at the St. Gallen International Breast Cancer Consensus Meeting in Vienna, Austria.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.